Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond



Rating:

Share or cite this content

Citations should be made in the following way:
C. Baratto (Milano, Italy), S. Caravita (Milano, Italy), C. Dewachter (Bruxelles, Belgium), G. Parati (Milano, Italy), J. Vachiéry (Bruxelles, Belgium). Impact of 3-months COVID-19 lockdown on exercise capacity in stable pulmonary arterial hypertension. 3589

Member's Comments

No comment yet.

Related content which might interest you: Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension Source: Eur Respir J 2013; 42: 414-424 Year: 2013 Exercise training in pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 641s Year: 2006 Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 393-398 Year: 2008 Impact of insomnia on exercise capacity and quality of life in patients with pulmonary arterial hypertension Source: International Congress 2017 – PAH and CTEPH Year: 2017 Functional impact of exercise pulmonary hypertension in patients with borderline pulmonary arterial pressure Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Pulmonary haemodynamics during exercise in patients with pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise testing in pulmonary arterial hypertension Year: 2005 Improvement in exercise capacity after a modified Potts shunt in an adult patient with pulmonary arterial hypertension Source: ERJ Open Res, 7 (4) 00287-2021; 10.1183/23120541.00287-2021 Year: 2021 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Effect of treatment on exercise endurance tolerance and ventilatory efficiency in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Hemodynamics as a substitute for exercise capacity endpoints in patients with pulmonary arterial hypertension (PAH): A model based assessment for sildenafil Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Demand for exercise training in patients with pulmonary arterial hypertension in Scotland Source: Eur Respir J 2015; 46: 1513-1515 Year: 2015 Relationship between daily life activities and upper extremity exercise capacity in patients with pulmonary arterial hypertension Source: International Congress 2015 – Physiotherapy outcomes and treatment in different patient profiles Year: 2015 Patient perspectives on exercise training in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 The prevalence of ventilatory limitation at peak exercise in pulmonary arterial hypertension Source: International Congress 2014 – Alterations of exercise and lung function in different diseases Year: 2014 Effects of 12-week exercise training-related rehabilitation on exertional dyspnoea in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2015 – Clinical exercise physiology in health and disease Year: 2015 Long-term improvement of pulmonary haemodynamics and exercise capacity in patients with pulmonary hypertension and hypoventilation following NIPPV and influence of NIPPV adherence Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Prognostic value of systolic pulmonary artery pressure change at exercise in pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Deleterious effects of ß-blockers on exercise capacity and hemodynamics in portopulmonary hypertension Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Effect of long-term oxygen therapy on exercise capacity and quality of life in exercise-desaturating patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomized-sham-controlled cross-over trial Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008